Pharmaceutical - Johnson & Johnson, Eli Lilly

Filter

Popular Filters

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone…

Eli LillyHealthcareInvega SustennaJohnson & JohnsonNeurologicalNew ZealandPharmaceuticalPricingRisperdal ConstaZyprexa Relprevv

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide

24-06-2013

Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Back to top